Hopes and Questions raised by Alzheimer’s drug Leqembi (lecanemab)

By Judith Graham @ Kaiser Health News | August 17, 2023

The FDA has approved Leqem­bi, the first dis­­ease-mod­­i­­fy­ing treat­ment for ear­­ly-stage Alzheimer’s and a pre­cur­sor con­di­tion, mild cog­ni­tive impair­ment. Medicare has said it will pay for the ther­a­py. Med­ical cen­ters across the coun­try are scram­bling to final­ize poli­cies and pro­ce­dures for pro­vid­ing the med­ica­tion to patients, pos­si­bly by summer’s end or ear­ly autumn. It’s a…

Read More

On physical activity, neuroplasticity, depression, screen time, neuromodulation and more

By SharpBrains | October 29, 2021

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing this time eight sci­en­tif­ic reports and indus­try resources plus a few fun brain teasers. #1. Study finds ulti­mate hack to pro­tect teen brains from harm­ful screen time: Exer­cise (and good role-mod­­el­ing): “Girls who spent less than an hour on screens and boys who spent less than…

Read More

Six guidelines to navigate the Aduhelm controversy and (hopefully) help patients with Mild Cognitive Impairment and early-stage Alzheimer’s Disease

By Kaiser Health News | October 13, 2021

The approval of a con­tro­ver­sial new drug for Alzheimer’s dis­ease, Aduhelm, is shin­ing a spot­light on mild cog­ni­tive impair­ment — prob­lems with mem­o­ry, atten­tion, lan­guage or oth­er cog­ni­tive tasks that exceed changes expect­ed with nor­mal aging. After ini­tial­ly indi­cat­ing that Aduhelm could be pre­scribed to any­one with demen­tia, the Food and Drug Admin­is­tra­tion now spec­i­fies that…

Read More